U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products or Type A Medicated Articles Manufactured from Active Pharmaceutical Ingredients Considered to be Soluble in Aqueous Media
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products or Type A Medicated Articles Manufactured from Active Pharmaceutical Ingredients Considered to be Soluble in Aqueous Media September 2019

Download the Draft Guidance Document Read the Federal Register Notice
Draft

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2019-D-3764
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

This document describes how the Center for Veterinary Medicine (CVM) intends to evaluate requests for waiving the requirement for performing in vivo bioequivalence studies (biowaivers) for animal drugs administered orally as soluble powders or as Type A medicated articles manufactured from active pharmaceutical ingredients (APIs) considered to be soluble in aqueous media (water soluble APIs). This document expands upon CVM’s Guidance for Industry (GFI) #35, “Bioequivalence Guidance,” to include biowaivers for soluble powder oral dosage form products as well as Type A medicated articles manufactured from active pharmaceutical ingredients considered to be soluble in aqueous media, and it offers particular focus on criteria for the waiver of the requirements for submitting in vivo bioequivalence study data.  This guidance does not address Type A medicated articles manufactured from active pharmaceutical ingredients considered to be insoluble in aqueous media.

For further information regarding this document, contact the following individuals:

Biopharmaceutics and Pharmacokinetics:

Marilyn Martinez
Center for Veterinary Medicine (HFV-100)
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855
240-402-0635
email: Marilyn.Martinez@fda.hhs.gov


Manufacturing Chemistry/Solubility Concerns:

Catherine Finnegan
Center for Veterinary Medicine (HFV-140)
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855
240-402-0650
email: Catherine.Finnegan@fda.hhs.gov

Generic Drug Approval Requirements:

Ian S. Hendricks
Center for Veterinary Medicine (HFV-172)
Food and Drug Administration
7500 Standish Place
Rockville, MD 20855
240-402-0853
email: Ian.Hendricks@fda.hhs.gov

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-3764.